2.050USD-0.48%Mkt Cap: 3.59M USDP/E: 0.05Last update: 2026-05-26
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap3.59M USD
Enterprise Value-7.09M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.96M USD
Revenue/Share—
Last Price2.050 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.05
P/E (Forward)-0.78
PEG—
EV/EBITDA0.65
EV/Revenue—
P/S—
P/B0.18
EPS (TTM)38.89
EPS (Forward)-2.83
52W Range
1.9700% of range80.36
52W High80.36 USD
52W Low1.970 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-199.00%
ROA-137.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.19M USD
CapEx (TTM)3.00K USD
FCF Margin—
FCF Yield-211.74%
Net Debt-10.99M USD
Net Debt/EBITDA1.01
Balance Sheet
Debt/Equity0.01
Current Ratio14.21
Quick Ratio13.91
Book Value/Sh12.07 USD
Cash/Share6.239 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:28
Split DateJan 26, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)25.00 USD
Target Range10.00 USD – 40.00 USD
# Analysts2
Ownership
Shares Out.1.77M
Float1.77M
Insiders0.46%
Institutions1.59%
Short Interest
Short Ratio0.7d
Short % Float7.43%
Short % Out.7.43%
Shares Short107.37K
Short (prev mo.)112.44K
Technical
SMA 502.372 (-13.6%)
SMA 20024.11 (-91.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)37.61K
Avg Vol (10d)23.58K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—